logo BDSP

Base documentaire

  1. Fulltext. Pharmacogenetics.

    Article - En anglais


    Inter-individual variability in drug response is a major clinical problem.

    Adverse drug reactions (ADRs) are common, are responsible for a number of debilitating side effects following drug therapy and are a significant cause of death.

    It is now clear that much of the observed variability in drug response has a genetic basis, arising as a result of genetically-determined differences in drug absorption, disposition, metabolism or excretion.

    The best characterised pharmacogenetic polymorphisms are those within the phase I cytochrome P450 family of drug metabolising enzymes.

    One of these enzymes, CYP2D6 (debrisoquine hydroxlyase), metabolises one-quarter of all prescribed drugs and is inactive in 6% of the Caucasian population.

    Individuals at risk of developing ADRs as a result of genetically-determined variation in genes such as CYP2D6 can now be identified using DNA-based tests.

    A detailed knowledge of the genetic basis of individual drug response is potentially of major clinical and economic importance and could provide the basis for a rational approach to drug prescription.

    This would have significant benefits for human health.

    Mots-clés Pascal : Pharmacogénétique, Effet secondaire, Toxicité, Chimiothérapie, Prescription médicale, Métabolisme, Médicament, Exploration, Homme

    Mots-clés Pascal anglais : Pharmacogenetics, Secondary effect, Toxicity, Chemotherapy, Medical prescription, Metabolism, Drug, Exploration, Human

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0470038

    Code Inist : 002A31C02A2. Création : 22/03/2000.